Lodisure 1 mg tablets for cats

Authorised

- Amlodipine besilate

Product identification

Medicine name:
Lodisure 1 mg tablets for cats
Lodisure 1 mg Tablet
Lodisure 1 mg Comprimé
Lodisure 1 mg Tablette

Active substance:
Amlodipine besilate

Target species:
Cat

Route of administration:
Oral use

Product details

Active substance and strength:
Amlodipine besilate
1.40 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Withdrawal period by route of administration:

Oral use:

- **Cat**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QC08CA01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Belgium

Package description:
Blister made of PVC /aluminium / OPA with a push-through PVC-PVDC/aluminium lidding foil. Each blister contains 14 tablets.1 cardboard carton with 168 tablets.
Blister made of PVC /aluminium / OPA with a push-through PVC-PVDC/aluminium lidding foil. Each blister contains 14 tablets.1 cardboard carton with 28 tablets.
Blister made of PVC /aluminium / OPA with a push-through PVC-PVDC/aluminium lidding foil. Each blister contains 14 tablets.1 cardboard carton with 84 tablets.
Blister made of PVC /aluminium / OPA with a push-through PVC-PVDC/aluminium lidding foil. Each blister contains 14 tablets.1 cardboard carton with 56 tablets.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Dechra Regulatory B.V.

Marketing authorisation date:

8/02/2021

Manufacturing sites for batch release:
Lelypharma B.V.

Responsible authority:
Federal Agency For Medicines And Health Products

Authorisation number:
BE-V579733

Date of authorisation status change:
8/02/2021

Reference member state:
Netherlands

Procedure number:
NL/V/0339/001

Concerned member states:
Austria Belgium Bulgaria Croatia Czechia Denmark Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 20/09/2023
Updated on: 22/09/2023
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet and Labelling

Combined File of all Documents

Labelling

This document does not exist in this language (English). You can find it in another language below.
